Tango Therapeutics (TNGX) Net Equity Issued and Repurchased (2020 - 2024)
Tango Therapeutics (TNGX) posted quarterly Net Equity Issued and Repurchased of $41.7 million for Q1 2024, up 166792.0% quarter-over-quarter from $25000.0 in Q4 2020.
Tango Therapeutics (TNGX) Net Equity Issued and Repurchased (2020 - 2024) Analysis & Trends
Tango Therapeutics' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $41.7 million for Q1 2024.
- In Q1 2024, Net Equity Issued and Repurchased changed N/A year-over-year to $41.7 million; the TTM figure through Sep 2024 stood at $41.7 million (changed N/A YoY), while the FY2020 annual figure was $25000.0, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q1 2024 stood at $41.7 million, up from $25000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $41.7 million in Q1 2024, with the low at $25000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 41.72 Mn |
| Mar 31, 2024 | 41.72 Mn |
| Dec 31, 2020 | 25,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 25,000.00 |
| Sep 30, 2020 | 25,000.00 |
| Jun 30, 2020 | 25,000.00 |
| Jun 30, 2020 | 25,000.00 |